This competition is designed to recognize outstanding research achievements by residents and students in emergency medicine.
Submissions for AAEM21 competitions are now closed.
The top six abstracts will be selected for oral presentation at AAEM21. All other abstract submissions are invited to display their research as a poster. The presenter of the oral abstract judged to represent the most outstanding research achievement will receive a $3,000 honorarium, while second and third place will receive $1,500 and $500 honoraria, respectively.
Please read the abstract submission instructions carefully. The deadline and space requirements are strictly enforced in order to give all authors an equal opportunity to submit their data in the same amount of space and under the same time constraints.
You will need to submit the presenting author’s name, address, telephone, and fax numbers, as well as an email address. Only the presenting author listed on the submission form will be notified of abstract acceptance. The presenting author must be a resident or student.
Indicate what monies have funded the research.
In accordance with the essentials and standards set forth by the Accreditation Council for Continuing Medical Education, as well as guidelines proposed by the Food and Drug Administration and endorsed by the American Medical Association, an author with a conflict of interest with the content of their abstract must disclose that conflict prior to presentation. A conflict of interest includes, but is not limited to, any relevant financial relationship in a company, product or procedure mentioned in the abstract or in the presentation to be given at the conference. The authors must complete the disclosure form included in the electronic submission. A conflict in and of itself will not eliminate an abstract from consideration.
No abstract published as an article on or before February 9, 2021, may be submitted for this competition. Abstracts that have been presented at the national meetings of other organizations should not be submitted for consideration. You cannot submit the same abstract for this and the AAEM/RSA & WestJEM Population Health Research Competition.
Any studies involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association (Clinical Research 1966; 14:103) and must meet all the requirements governing informed consent of the country in which the research was performed.
Oral abstracts presented at AAEM’s 27th Annual Scientific Assembly may be published in a future issue of the Journal of Emergency Medicine. Ownership of abstracts not accepted reverts to the authors.
Submitters will be asked for permission for AAEM to use accepted abstracts for online continuing medical education purposes. All authors and contributors will be appropriately credited.
The presenting author of all abstracts submitted by February 9, 2021, will receive notification of acceptance or rejection in April 2021.
Withdrawals and revisions must be received in writing to firstname.lastname@example.org by February 15, 2021. No changes can be submitted after that date.
Objectives: A precise statement of the purpose of the study or the pre-study hypothesis. This may be preceded by a brief introduction summarizing past work or relevant controversies that place the study in perspective.
Methods: A brief statement of the methods used, including pertinent information about the study design, setting, participants, subjects, interventions, and observations.
Results: A summary of the results presented in sufficient detail to support the conclusions.
Conclusions: Conclusions should be succinctly stated and firmly supported by the data presented. Note important limitations.
Salameh Ja, Dong Fa, Mousselli Ma, Toy Ja, Massoud Ra, Chandowani Da,e, O’Bosky Kb, Luo-Owen Xb, Wong Dc,e, Vara Rc, Comunale Md,e, Neeki MMa,e.
aDepartment of Emergency Medicine, Arrowhead Regional Medical Center, Colton, CA
bDepartment of General Surgery, Loma Linda University Medical Center, Loma Linda, CA
cDepartment of Surgery, Arrowhead Regional Medical Center, Colton, CA
dDepartment of Anesthesia, Arrowhead Regional Medical Center, Colton, CA
eCalifornia University of Sciences and Medicine, Colton, CA
No funding was received for this project.
Conflicts of Interest
By the AAEM abstract submission requirements, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. No author has professional or financial relationships with any companies that are relevant to this study. There are no conflicts of interest or sources of funding to declare
Trauma can pose a severe threat to life and accounts for more than 5.8 million deaths worldwide. Trauma can rapidly lead to coagulopathies causing hemorrhagic shock and death. This study aims to evaluate the safety and efficacy of tranexamic acid (TXA) use in the hospital setting for cases of traumatic hemorrhagic shock.
Patients from 2 different trauma centers who sustained blunt or penetrating trauma with signs of hemorrhagic shock from March 2015 through June 2018 were considered for TXA treatment. A retrospective control group was formed from patients seen in the past five years who were not administered TXA and matched based on age, gender, ISS, and mechanism of injury. The primary outcome of this study was mortality measured at 24 hours, 48 hours, and 28 days. Secondary outcomes included total blood products, hospital length of stay (LOS), ICU LOS, and adverse events.
Both the hospital TXA and control cohorts consisted of 280 patients. The hospital TXA group had statistically significant lower mortality at 28 days (1.1% vs 5%, p=0.0067); used fewer units of blood products (median of 4 vs 7 units p=0.0005); and had a shorter hospital LOS (median of 7 vs 12 days, p<0.0001). There was no significant difference in adverse effects for TXA versus control. Subgroup analyses were conducted on patients who had and ISS ≥16, and those transfused ≥10 units of blood. The ISS ≥16 subgroup showed a statistically significant lower mortality at 28 days for TXA compared to control. While not significant, those transfused ≥10 units of blood showed a trend towards decreased mortality for TXA versus control.
This study identified a statistically significant reduction in mortality at 28 days after TXA administration in trauma patients, and a trend towards decreased mortality at 24 hours, and 48 hours. Our study shows that TXA may be used safely and efficaciously for trauma-induced hemorrhagic shock in the hospital trauma system.